Aligos Therapeutics Inc. (ALGS) NASDAQ
$0.66 (0.02) (-3.55%)
Market Cap: $51.16M
As of 05/16/24 04:00 PM EDT. Market closed.
Aligos Therapeutics Inc. (ALGS)
NASDAQ
$0.66
(0.02) (-3.55%)
Market Cap: $51.16M
As of 05/16/24 04:00 PM EDT. Market closed.
Add to Portfolio
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
85
URL
Address
.
PRICE CHART FOR ALIGOS THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$0.68
Days Range
$0.65 - $0.70
52 week range
$0.54 - $1.22
Volume
79
Avg. Volume (30 days)
198,814
Market Cap
$51.16M
Dividend Yield
-
P/E
(0.51)
Shares Outstanding
78,109,927
Open
-
Previous Close
$0.68
Days Range
$0.65 - $0.70
52 week range
$0.54 - $1.22
Volume
79
Avg. Volume (30 days)
198,814
Market Cap
$51.16M
Dividend Yield
-
P/E
(0.51)
Shares Outstanding
78,109,927
FINANCIAL STATEMENTS FOR ALIGOS THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ALIGOS THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Nuechterlein Carole | Director | Oct 25, 2023 | Buy | $0.76 | 7,933,601 | 6,004,149 | 11,025,941 | Oct 27, 2023, 04:15 PM |
| BLATT LAWRENCE | Chief Executive Officer | Oct 25, 2023 | Option Exercise | $0.76 | 610,277 | 461,858 | 1,847,575 | Oct 27, 2023, 04:14 PM |
| Scopa James Paul | Director | Oct 25, 2023 | Option Exercise | $0.76 | 183,083 | 138,557 | 183,083 | Oct 27, 2023, 04:13 PM |
| Novo Holdings A/S | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 2,614,563 | Oct 22, 2020, 04:31 PM |
| Woiwode Thomas | Director | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 862,444 | Oct 20, 2020, 05:00 PM |
| Vivo Capital VIII, LLC | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 66,733 | 1,000,995 | 430,372 | Oct 20, 2020, 04:59 PM |
| Vivo Capital VIII, LLC | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 483,267 | 7,249,005 | 3,116,658 | Oct 20, 2020, 04:59 PM |
| Versant Venture Capital VI, L.P. | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 862,444 | Oct 20, 2020, 04:58 PM |
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Nuechterlein Carole | Director | 10/25/2023 | 6,004,149 |
| BLATT LAWRENCE | Chief Executive Officer | 10/25/2023 | 461,858 |
| Scopa James Paul | Director | 10/25/2023 | 138,557 |
| Novo Holdings A/S | 10% Owner | 10/20/2020 | 3,000,000 |
| Woiwode Thomas | Director | 10/20/2020 | 3,000,000 |
| Vivo Capital VIII, LLC | 10% Owner | 10/20/2020 | 1,000,995 |
| Vivo Capital VIII, LLC | 10% Owner | 10/20/2020 | 7,249,005 |
| Versant Venture Capital VI, L.P. | 10% Owner | 10/20/2020 | 3,000,000 |
FUNDS WITH A POSITION IN ALIGOS THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| VIVO CAPITAL, LLC | 3,547,030 | 0.27% | No change | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,464,505 | 0.00456% | New | Other |
| BAKER BROS. ADVISORS LP | 2,076,400 | 0.03% | No change | Other |
| HHLR ADVISORS, LTD. | 1,906,191 | 0.04% | No change | Other |
| RENAISSANCE TECHNOLOGIES LLC | 808,260 | 0.00124% | 64.96% | Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 500,000 | 0.04% | New | Value |
| GEODE CAPITAL MANAGEMENT, LLC | 373,056 | 0.00003% | 16.2% | Other |
| BLACKROCK INC. | 303,755 | 0.00001% | 2.57% | Other |
BUYBACK ANNOUNCEMENT(S) FOR ALIGOS THERAPEUTICS INC
LOADING...